FASN and breast cancer: Currently, TVB-2640 is the only selective FASN inhibitor in clinical trials for the treatment of advanced solid tumors, including HER2+ advanced breast cancer, high-grade astrocytoma, colon cancer, and non-small cell lung carcinoma with mutations in KRAS.